CN112262214A - 病毒载体及包装细胞系 - Google Patents

病毒载体及包装细胞系 Download PDF

Info

Publication number
CN112262214A
CN112262214A CN201980037729.7A CN201980037729A CN112262214A CN 112262214 A CN112262214 A CN 112262214A CN 201980037729 A CN201980037729 A CN 201980037729A CN 112262214 A CN112262214 A CN 112262214A
Authority
CN
China
Prior art keywords
cell
nucleic acid
receptor
lentiviral
lentiviral particle
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980037729.7A
Other languages
English (en)
Chinese (zh)
Inventor
A·沙伦伯格
L·贝茨
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Youmojia Biopharmaceutical Co ltd
Original Assignee
Youmojia Biopharmaceutical Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Youmojia Biopharmaceutical Co ltd filed Critical Youmojia Biopharmaceutical Co ltd
Publication of CN112262214A publication Critical patent/CN112262214A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70532—B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15032—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15051—Methods of production or purification of viral material
    • C12N2740/15052—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16032—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16051—Methods of production or purification of viral material
    • C12N2740/16052—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Endocrinology (AREA)
  • Nutrition Science (AREA)
  • Mycology (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201980037729.7A 2018-04-12 2019-04-11 病毒载体及包装细胞系 Pending CN112262214A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862656823P 2018-04-12 2018-04-12
US62/656,823 2018-04-12
PCT/US2019/026923 WO2019200056A2 (en) 2018-04-12 2019-04-11 Viral vectors and packaging cell lines

Publications (1)

Publication Number Publication Date
CN112262214A true CN112262214A (zh) 2021-01-22

Family

ID=66287035

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980037729.7A Pending CN112262214A (zh) 2018-04-12 2019-04-11 病毒载体及包装细胞系

Country Status (10)

Country Link
US (3) US12215337B2 (cg-RX-API-DMAC7.html)
EP (1) EP3775231A2 (cg-RX-API-DMAC7.html)
JP (1) JP7721436B2 (cg-RX-API-DMAC7.html)
CN (1) CN112262214A (cg-RX-API-DMAC7.html)
AU (2) AU2019252285B2 (cg-RX-API-DMAC7.html)
BR (1) BR112020020887A2 (cg-RX-API-DMAC7.html)
CA (1) CA3096458A1 (cg-RX-API-DMAC7.html)
IL (1) IL277936A (cg-RX-API-DMAC7.html)
SG (1) SG11202009975TA (cg-RX-API-DMAC7.html)
WO (1) WO2019200056A2 (cg-RX-API-DMAC7.html)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114981441A (zh) * 2019-10-16 2022-08-30 优莫佳生物制药股份有限公司 用于通用受体疗法的逆转录病毒载体
US12215337B2 (en) 2018-04-12 2025-02-04 Umoja Biopharma, Inc. Viral vectors and packaging cell lines

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4282419A1 (en) 2012-12-20 2023-11-29 Purdue Research Foundation Chimeric antigen receptor-expressing t cells as anti-cancer therapeutics
US11325948B2 (en) 2016-03-19 2022-05-10 Exuma Biotech Corp. Methods and compositions for genetically modifying lymphocytes to express polypeptides comprising the intracellular domain of MPL
US12590321B2 (en) 2016-03-19 2026-03-31 Exuma Biotech Corp. Methods and compositions for genetically modifying and expanding lymphocytes and regulating the activity thereof
US11111505B2 (en) 2016-03-19 2021-09-07 Exuma Biotech, Corp. Methods and compositions for transducing lymphocytes and regulating the activity thereof
EP3439675A4 (en) 2016-04-08 2019-12-18 Purdue Research Foundation METHOD AND COMPOSITIONS FOR CAR-T CELL THERAPY
WO2018160622A1 (en) 2017-02-28 2018-09-07 Endocyte, Inc. Compositions and methods for car t cell therapy
US11311576B2 (en) 2018-01-22 2022-04-26 Seattle Children's Hospital Methods of use for CAR T cells
AU2019225174B2 (en) 2018-02-23 2025-11-20 Endocyte, Inc. Sequencing method for CAR T cell therapy
US20220017920A1 (en) 2018-11-21 2022-01-20 Umoja Biopharma, Inc. Multicistronic vector for surface engineering lentiviral particles
AU2021213735A1 (en) 2020-01-30 2022-09-22 Umoja Biopharma, Inc. Bispecific transduction enhancer
US20230201440A1 (en) * 2020-05-08 2023-06-29 Innovative Cellular Therapeutics Holdings, Ltd. System and method for gene and/or cellular therapy
EP4247963A1 (en) * 2020-11-20 2023-09-27 Umoja Biopharma, Inc. Vector system for delivery of multiple polynucleotides and uses thereof
AU2022212952A1 (en) 2021-01-27 2023-08-10 Umoja Biopharma, Inc. Lentivirus for generating cells expressing anti-cd19 chimeric antigen receptor
IL316109A (en) * 2022-05-06 2024-12-01 Umoja Biopharma Inc Viral particle with mixed molecules on the surface
TW202434735A (zh) * 2022-11-04 2024-09-01 美商烏莫賈生物製藥股份有限公司 展示黏著分子融合的顆粒
KR20250121163A (ko) * 2022-11-04 2025-08-11 우모자 바이오파마 인코포레이티드 융합 분자를 디스플레이하는 렌티바이러스 입자 및 이의 용도
EP4694916A1 (en) 2023-04-14 2026-02-18 SOTIO Biotech Inc. Engineered immune cells for treating cancer in combination with il-2/il-15 receptor ?? agonists
WO2024215987A1 (en) 2023-04-14 2024-10-17 Sotio Biotech Inc. IMMUNE CELLS FOR TREATING CANCER IN COMBINATION WITH IL-15/IL-15Rα CONJUGATES
WO2024223847A1 (en) 2023-04-27 2024-10-31 Miltenyi Biotec B.V. & Co. KG Pseudotyped retroviral vector particle with anti-cd3 display
EP4713467A1 (en) * 2023-05-15 2026-03-25 Umoja Biopharma, Inc. Lentiviral delivery of anti-cd20 chimeric antigen receptors
WO2024238769A2 (en) * 2023-05-16 2024-11-21 The Regents Of The University Of California Inhibitory chimeric antigen receptors that reduce car-t cell "on-target, off-tumor" toxicity
WO2025078492A1 (en) 2023-10-13 2025-04-17 Miltenyi Biotec B.V. & Co. KG Cd3-targeted nipah-pseudotyped lentiviral vector particles
WO2025162379A1 (zh) * 2024-02-01 2025-08-07 深圳市济因生物科技有限公司 一种多肽及包含所述多肽基因的病毒载体

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104395463A (zh) * 2012-04-30 2015-03-04 达特茅斯大学理事会 T细胞受体缺陷型t细胞组合物
WO2015090229A1 (en) * 2013-12-20 2015-06-25 Novartis Ag Regulatable chimeric antigen receptor
WO2017015427A1 (en) * 2015-07-21 2017-01-26 Novartis Ag Methods for improving the efficacy and expansion of immune cells
WO2017201432A2 (en) * 2016-05-19 2017-11-23 Jounaidi Youssef Tethered interleukin-2 to its receptor il-2rbeta, a platform to enhance natural killer and regulatory t cell activity
CN107406860A (zh) * 2015-03-02 2017-11-28 Ucl商务股份有限公司 逆转录病毒载体和慢病毒载体
CN107531800A (zh) * 2014-07-25 2018-01-02 赛拉福柯蒂斯公司 用于嵌合抗原受体分子的调控表达的慢病毒载体

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
US5739018A (en) 1996-08-07 1998-04-14 The Regents Of The University Of California Packaging cell lines for pseudotyped retroviral vectors
US6207455B1 (en) 1997-05-01 2001-03-27 Lung-Ji Chang Lentiviral vectors
IL132463A0 (en) 1997-05-13 2001-03-19 Univ North Carolina Lentivirus - based gene transfer vectors
US6136597A (en) 1997-09-18 2000-10-24 The Salk Institute For Biological Studies RNA export element
US5994136A (en) 1997-12-12 1999-11-30 Cell Genesys, Inc. Method and means for producing high titer, safe, recombinant lentivirus vectors
WO2000055378A1 (en) 1999-03-16 2000-09-21 Dana-Farber Cancer Institute, Inc. Lentiviral vector system for high quantity screening
HK1050210B (en) 1999-10-12 2007-08-24 Institut Pasteur Lentiviral triplex dna, and vectors and recombinant cells containing lentiviral triplex dna
US7939059B2 (en) 2001-12-10 2011-05-10 California Institute Of Technology Method for the generation of antigen-specific lymphocytes
US7135339B2 (en) 2003-11-20 2006-11-14 University Of Iowa Research Foundation Methods for producing and using in vivo pseudotyped retroviruses using envelope glycoproteins from lymphocytic choriomeningitis virus (LCMV)
EP1769078A1 (en) 2004-07-01 2007-04-04 VIRxSYS Corporation Vector packaging cell line
JP2006085744A (ja) 2004-09-14 2006-03-30 Matsushita Electric Ind Co Ltd 磁気記録再生装置及びそのテープスレッディング方法
WO2007095201A2 (en) 2006-02-15 2007-08-23 The Regents Of The University Of California Pseudotyped retroviral vectors and methods of use thereof
CA2651174A1 (en) 2006-05-03 2007-11-15 Government Of The United States Of America, Represented By The Secretary , Department Of Health And Human Services Chimeric t cell receptors and related materials and methods of use
US8293685B2 (en) 2007-07-26 2012-10-23 The Regents Of The University Of California Methods for enhancing bacterial cell display of proteins and peptides
GB0920775D0 (en) 2009-11-26 2010-01-13 King S College Cells
WO2013188693A1 (en) 2012-06-15 2013-12-19 Imaginab, Inc. Antigen binding constructs to cd3
EP4282419A1 (en) 2012-12-20 2023-11-29 Purdue Research Foundation Chimeric antigen receptor-expressing t cells as anti-cancer therapeutics
EP3925618A1 (en) 2013-07-29 2021-12-22 2seventy bio, Inc. Multipartite signaling proteins and uses thereof
ES2857226T3 (es) 2014-03-15 2021-09-28 Novartis Ag Receptor de antígeno quimérico regulable
US20170335281A1 (en) 2014-03-15 2017-11-23 Novartis Ag Treatment of cancer using chimeric antigen receptor
CN113604491A (zh) 2014-05-02 2021-11-05 宾夕法尼亚大学董事会 嵌合自身抗体受体t细胞的组合物和方法
GB201412494D0 (en) 2014-07-14 2014-08-27 Ospedale San Raffaele And Fond Telethon Vector production
TWI751102B (zh) 2014-08-28 2022-01-01 美商奇諾治療有限公司 對ｃｄ１９具專一性之抗體及嵌合抗原受體
US20180127781A1 (en) 2015-01-21 2018-05-10 Fred Hutchinson Cancer Research Center Cocal envelope pseudotyped retroviral vector producer cells
JP7237449B2 (ja) 2015-02-27 2023-03-13 アイセル・ジーン・セラピューティクス・エルエルシー 血液系腫瘍を標的としたキメラ抗体受容体（ＣＡＲｓ）の構成およびその使用方法
US10584157B2 (en) * 2015-03-16 2020-03-10 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd Isolated peptides derived from the B7 ligand dimer interface and uses thereof
GB201514875D0 (en) 2015-08-20 2015-10-07 Autolus Ltd Receptor
CU24649B1 (es) 2016-03-19 2023-02-13 Exuma Biotech Corp Retrovirus recombinantes incompetentes de replicación para la transducción de linfocitos y expansión regulada de los mismos
EP3439675A4 (en) 2016-04-08 2019-12-18 Purdue Research Foundation METHOD AND COMPOSITIONS FOR CAR-T CELL THERAPY
US20200165302A1 (en) 2016-09-14 2020-05-28 Université Catholique de Louvain Modified vsv-g and vaccines thereof
CN110191955B (zh) 2016-12-13 2024-05-31 西雅图儿童医院（Dba西雅图儿童研究所） 在体外和体内对工程化的细胞中表达的化学物质诱导的信号传导复合物进行外源性药物激活的方法
WO2018132508A1 (en) 2017-01-10 2018-07-19 The General Hospital Corporation Methods and compositions relating to ex vivo culture and modulation of t cells
US11649288B2 (en) 2017-02-07 2023-05-16 Seattle Children's Hospital Phospholipid ether (PLE) CAR T cell tumor targeting (CTCT) agents
CA3053534A1 (en) 2017-02-17 2018-08-23 Purdue Research Foundation Targeted ligand-payload based drug delivery for cell therapy
WO2018160622A1 (en) 2017-02-28 2018-09-07 Endocyte, Inc. Compositions and methods for car t cell therapy
EP3735460A4 (en) 2017-09-18 2021-08-11 Exuma Biotech Corp. METHODS AND COMPOSITIONS FOR THE GENETIC MODIFICATION AND EXPANSION OF LYMPHOCYTES AND THE REGULATION OF THE ACTIVITY OF THE LATTER
JP2021505621A (ja) 2017-12-07 2021-02-18 ダーマヴァント サイエンシーズ ゲーエムベーハー Ｐｄｅ−４阻害剤の局所軟膏製剤および皮膚状態の治療におけるそれらの使用
US11311576B2 (en) 2018-01-22 2022-04-26 Seattle Children's Hospital Methods of use for CAR T cells
US12312416B2 (en) 2018-02-06 2025-05-27 Seattle Children's Hospital Fluorescein-specific cars exhibiting optimal t cell function against FL-PLE labelled tumors
WO2019157533A1 (en) 2018-02-12 2019-08-15 The General Hospital Corporation Chimeric antigen receptors targeting the tumor microenvironment
CA3096458A1 (en) 2018-04-12 2019-10-17 Umoja Biopharma, Inc. Viral vectors and packaging cell lines
KR20210074274A (ko) 2018-08-06 2021-06-21 시애틀 칠드런즈 호스피탈 디/비/에이 시애틀 칠드런즈 리서치 인스티튜트 합텐 표지된 세포로의 키메라 항원 수용체 t 세포의 자극을 위한 방법 및 조성물
CN112543651B (zh) 2018-08-07 2023-06-02 普渡研究基金会 使car t细胞恢复活力
US20220017920A1 (en) 2018-11-21 2022-01-20 Umoja Biopharma, Inc. Multicistronic vector for surface engineering lentiviral particles
CN113692285A (zh) 2018-11-30 2021-11-23 朱诺治疗学股份有限公司 在过继细胞疗法中给药和治疗b细胞恶性肿瘤的方法
CA3154281A1 (en) 2019-10-16 2021-04-22 Andrew Scharenberg Retroviral vector for universal receptor therapy
CA3184784A1 (en) 2020-05-27 2021-12-02 The Medical College Of Wisconsin, Inc. Improved lentiviral vector transfer plasmid and methods of use
US11517814B2 (en) 2020-09-03 2022-12-06 Alan Chalmers Flavour system
EP4247963A1 (en) 2020-11-20 2023-09-27 Umoja Biopharma, Inc. Vector system for delivery of multiple polynucleotides and uses thereof
AU2022212952A1 (en) 2021-01-27 2023-08-10 Umoja Biopharma, Inc. Lentivirus for generating cells expressing anti-cd19 chimeric antigen receptor
IL316109A (en) 2022-05-06 2024-12-01 Umoja Biopharma Inc Viral particle with mixed molecules on the surface

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170253857A1 (en) * 2009-10-29 2017-09-07 The Trustees Of Dartmouth College T-cell receptor-deficient t cell compositions
CN104395463A (zh) * 2012-04-30 2015-03-04 达特茅斯大学理事会 T细胞受体缺陷型t细胞组合物
WO2015090229A1 (en) * 2013-12-20 2015-06-25 Novartis Ag Regulatable chimeric antigen receptor
CN107531800A (zh) * 2014-07-25 2018-01-02 赛拉福柯蒂斯公司 用于嵌合抗原受体分子的调控表达的慢病毒载体
CN107406860A (zh) * 2015-03-02 2017-11-28 Ucl商务股份有限公司 逆转录病毒载体和慢病毒载体
WO2017015427A1 (en) * 2015-07-21 2017-01-26 Novartis Ag Methods for improving the efficacy and expansion of immune cells
WO2017201432A2 (en) * 2016-05-19 2017-11-23 Jounaidi Youssef Tethered interleukin-2 to its receptor il-2rbeta, a platform to enhance natural killer and regulatory t cell activity

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12215337B2 (en) 2018-04-12 2025-02-04 Umoja Biopharma, Inc. Viral vectors and packaging cell lines
CN114981441A (zh) * 2019-10-16 2022-08-30 优莫佳生物制药股份有限公司 用于通用受体疗法的逆转录病毒载体

Also Published As

Publication number Publication date
JP2021520853A (ja) 2021-08-26
BR112020020887A2 (pt) 2021-04-06
SG11202009975TA (en) 2020-11-27
WO2019200056A3 (en) 2020-01-09
JP7721436B2 (ja) 2025-08-12
US20250122533A1 (en) 2025-04-17
AU2025237995A1 (en) 2025-10-16
CA3096458A1 (en) 2019-10-17
EP3775231A2 (en) 2021-02-17
US20250122532A1 (en) 2025-04-17
US20210147871A1 (en) 2021-05-20
AU2019252285B2 (en) 2025-06-26
US12215337B2 (en) 2025-02-04
AU2019252285A1 (en) 2020-10-29
IL277936A (en) 2020-11-30
JP2024100972A (ja) 2024-07-26
WO2019200056A2 (en) 2019-10-17

Similar Documents

Publication Publication Date Title
AU2019252285B2 (en) Viral vectors and packaging cell lines
US12599678B2 (en) Methods and compositions for genomic integration
KR102729768B1 (ko) 트랜스제닉 선택 방법 및 조성물
AU2019279084B2 (en) Diverse antigen binding domains, novel platforms and other enhancements for cellular therapy
AU2017323629B9 (en) PD-1 homing endonuclease variants, compositions, and methods of use
AU2016232146B2 (en) Optimized liver-specific expression systems for FVIII and FIX
CN110770348B (zh) 嵌合抗原受体细胞的制备及其用途
US20250135031A1 (en) Single-vector gene construct comprising insulin and glucokinase genes
AU774643B2 (en) Compositions and methods for use in recombinational cloning of nucleic acids
KR20200032174A (ko) 강화된 키메라 항원 수용체 및 이의 용도
KR20240004253A (ko) 오토펄린 듀얼 벡터 시스템을 사용한 감각신경성 난청을 치료하기 위한 방법
KR20240022575A (ko) 아머링된 키메라 수용체 및 이의 사용 방법
KR20220041214A (ko) Il-1 수퍼패밀리의 사이토카인의 시공적 제한 활성으로 무장된 면역반응성 세포
CN115768890A (zh) 通过分子和物理启动对t细胞免疫疗法的热控制
CN115867295A (zh) 用于靶向hpv感染细胞的组合物和方法
CN116323942A (zh) 用于基因组编辑的组合物及其使用方法
CN117120085A (zh) Sars-cov-2免疫原性组合物、疫苗和方法
KR102712198B1 (ko) 재조합 발생이 최소화된 유전자치료 벡터, 상기 벡터를 포함하는 재조합 레트로바이러스 및 상기 재조합 레트로바이러스를 포함하는 암의 예방 또는 치료용 약학 조성물
CN116323924B (zh) 基因疗法载体、包含载体的重组逆转录病毒和用于预防或治疗癌症的药物组合物
HK40091239A (zh) 用於靶向hpv感染细胞的组合物和方法
CA2974235C (en) Single-vector gene construct comprising insulin and glucokinase genes
KR20200111198A (ko) 양방향성 chef1 벡터

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination